Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nuvo Research Receives €4.4 Million Additional Funding to Develop WF10

Published: Thursday, December 27, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Total cost of the development program is estimated to be €6.3 million.

Nuvo Research Inc. has announced that the Development Bank of Saxony (SAB) in Germany has agreed to provide Nuvo with up to €4.4 million of funding for the further development of its improved reformulated version of WF10 (Reformulated WF10).

The funding will take the form of a non-repayable reimbursement of specific development monies expended by Nuvo until July 2014.

The SAB funding will be used to support CMC activities, "in vitro" experiments and a number of preclinical studies relating to Reformulated WF10 for which Nuvo filed a US provisional patent in December 2011.

These studies are being conducted by Nuvo in partnership with the University of Leipzig and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig.

The total cost of this development program is estimated to be €6.3 million and the SAB committed to provide up to €4.4 million in funding to support these projects.

Nuvo will have certain contractual obligations to the SAB including the obligation to provide matching funding from its own resources of €1.9 million over the two year period ending in July 2014.

Nuvo will own or have exclusive global rights to commercially exploit all WF10 related intellectual property that comes from the funded projects.

In the fall of 2009, the SAB committed to provide funding over a three-year period of approximately €2.2 million for two WF10 development projects.

With the most recent commitment from the SAB, the total funding is approximately €6.6 million towards a €10.8 million development program.

"We are thrilled to expand our existing partnership with the SAB, the University of Leipzig and the Fraunhofer Institute by securing SAB funding that will allow us to continue with the development of WF10," said Dr. Henrich Guntermann, President of Nuvo's Immunology Group.

Dr. Guntermann continued, "WF10 is an extremely exciting compound with the potential to treat a broad range of medical conditions. We are pleased that the SAB recognizes WF10's potential and has chosen to partner with Nuvo."

Nuvo believes that WF10 has the potential to treat a wide range of medical conditions including auto immune disorders.

In 2010, Nuvo announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary and secondary end points with a p-value of less than 0.001.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuvo Research Announces 2013 Fourth Quarter & Year-End Results
Company will commence a Phase 2 study of WF10 with results expected in Q4 2014.
Friday, March 07, 2014
Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.
Friday, May 17, 2013
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!